GlassScriptPhysician profile
Jason R Sherman
NPI 1689896060
$1,657.12
in general payments reported to CMS, 2019-2025
12 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $56.31 · 2021: $287 · 2022: $303 · 2023: $305 · 2024: $54.05 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $610.49 | 2020-2023 | Xtampza |
| Abbott Laboratories | $308.50 | 2019-2025 | Proclaim |
| Abbvie INC. | $227.22 | 2021-2025 | |
| Corelink, LLC | $147.90 | 2023 | |
| Medtronic USA, INC. | $125.68 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $88.52 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.15 | 2021-2025 | Relistor |
| Pfizer INC. | $29.92 | 2024-2025 | |
| Biodelivery Sciences International, INC. | $17.09 | 2021 | |
| Nalu Medical, INC. | $16.18 | 2025 | Nalu Neurostimulation System |
| Astrazeneca Pharmaceuticals LP | $11.60 | 2019 | |
| Orthofix Medical, INC. | $3.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.